{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:45:36Z","timestamp":1790419536990,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":645,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100005089","name":"Beijing Municipal Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005089","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.exphem.2020.08.001","type":"journal-article","created":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T12:01:47Z","timestamp":1596715307000},"page":"87-95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Sirolimus is effective for primary relapsed\/refractory autoimmune cytopenia: a multicenter study"],"prefix":"10.1016","volume":"89","author":[{"given":"Hongmin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhou","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RunHui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2020.08.001_bib0001","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.pcl.2013.08.009","article-title":"Diagnosis and management of autoimmune cytopenias in childhood","volume":"60","author":"Teachey","year":"2013","journal-title":"Pediatr Clin North Am"},{"key":"10.1016\/j.exphem.2020.08.001_bib0002","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.autrev.2014.04.006","article-title":"Common variable immunodeficiency and autoimmunity\u2014an inconvenient truth","volume":"13","author":"Xiao","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.exphem.2020.08.001_bib0003","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/17474086.2018.1489720","article-title":"Autoimmune cytopenias in chronic lymphocytic leukemia: a concise review and treatment recommendations","volume":"11","author":"De Back","year":"2018","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.exphem.2020.08.001_bib0004","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/bjh.13866","article-title":"How I manage Evans syndrome and AIHA cases in children","volume":"172","author":"Miano","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2020.08.001_bib0005","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3324\/haematol.2010.036053","article-title":"New insights into childhood autoimmune hemolytic anemia: a French national observational study of 265 children","volume":"96","author":"Aladjidi","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2020.08.001_bib0006","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/00007890-199309000-00031","article-title":"Reversal of ongoing heart, kidney, and pancreas allograft rejection and suppression of accelerated heart allograft rejection in the rat by rapamycin","volume":"56","author":"Chen","year":"1993","journal-title":"Transplantation"},{"key":"10.1016\/j.exphem.2020.08.001_bib0007","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2015-07-657981","article-title":"Sirolimus is effective in relapsed\/refractory autoimmune cytopenias: results of a prospective multi-institutional trial","volume":"127","author":"Bride","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2020.08.001_bib0008","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/bjh.13010","article-title":"Sirolimus for the treatment of multi-resistant autoimmune haemolytic anaemia in children","volume":"167","author":"Miano","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2020.08.001_bib0009","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/MPH.0000000000000818","article-title":"Sirolimus as an effective agent in the treatment of immune thrombocytopenia (ITP) and Evans syndrome (ES): a single institution's experience","volume":"39","author":"Jasinski","year":"2017","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.exphem.2020.08.001_bib0010","article-title":"Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the First International Consensus Meeting","volume":"41","author":"Jager","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.exphem.2020.08.001_bib0011","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2020.08.001_bib0012","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1080\/1744666X.2018.1521722","article-title":"Current and emerging treatment options for autoimmune hemolytic anemia","volume":"14","author":"Barcellini","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.exphem.2020.08.001_bib0013","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/art.1780370219","article-title":"Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus","volume":"37","author":"Warner","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.exphem.2020.08.001_bib0014","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1002\/art.22085","article-title":"Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus","volume":"54","author":"Fernandez","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.exphem.2020.08.001_bib0015","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/bjh.13533","article-title":"Mycophenolate mofetil and sirolimus as second or further line treatment in children with chronic refractory primitive or secondary autoimmune cytopenias: a single centre experience","volume":"171","author":"Miano","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2020.08.001_bib0016","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/548085","article-title":"Effects of rapamycin combined with low dose prednisone in patients with chronic immune thrombocytopenia","volume":"2013","author":"Li","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.exphem.2020.08.001_bib0017","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3389\/fmed.2020.00110","article-title":"Sirolimus as rescue therapy for refractory\/relapsed immune thrombocytopenia: results of a single-center, prospective, single-arm study","volume":"7","author":"Feng","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.exphem.2020.08.001_bib0018","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1007\/s00277-018-3431-5","article-title":"Successful treatment of refractory\/relapsed acquired pure red cell aplasia with sirolimus","volume":"97","author":"Long","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.exphem.2020.08.001_bib0019","first-page":"297","article-title":"Naturally occurring regulatory T cells and interleukins 10 and 12 in the pathogenesis of idiopathic warm autoimmune hemolytic anemia","volume":"21","author":"Ahmad","year":"2011","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.exphem.2020.08.001_bib0020","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1600-0609.2006.00780.x","article-title":"Abnormality of CD4(+)CD25(+) regulatory T cells in idiopathic thrombocytopenic purpura","volume":"78","author":"Liu","year":"2007","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.exphem.2020.08.001_bib0021","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s00277-016-2629-7","article-title":"Cyclosporine restores hematopoietic function by compensating for decreased Tregs in patients with pure red cell aplasia and acquired aplastic anemia","volume":"95","author":"Dao","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.exphem.2020.08.001_bib0022","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.autrev.2017.04.012","article-title":"Pathogenesis of immune thrombocytopenia","volume":"16","author":"Audia","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.exphem.2020.08.001_bib0023","first-page":"813","article-title":"Sirolimus and mTOR inhibitors: a review of side effects and specific management in solid organ transplantation","volume":"42","author":"Nguyen","year":"2019","journal-title":"Drug Saf"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X20303076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X20303076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:36:09Z","timestamp":1759566969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X20303076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":23,"alternative-id":["S0301472X20303076"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2020.08.001","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sirolimus is effective for primary relapsed\/refractory autoimmune cytopenia: a multicenter study","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2020.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 ISEH -- Society for Hematology and Stem Cells. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}